Should I buy Merit Medical Systems, Inc. (MMSI) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Merit Medical Systems, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Raymond James | 65 % | +18.7 % | 26 | $102 +14% |
| Canaccord Genuity | 63 % | +9.9 % | 19 | $94 +5% |
| Piper Sandler | 53 % | +9.5 % | 19 | $106 +18% |
| Barrington Research | 46 % | +2.7 % | 24 | $107 +19% |
| Needham | 39 % | -1.8 % | 31 | $101 +13% |
| Wells Fargo | 30 % | -22.1 % | 10 | $83 -7% |
✅ Reasons to believe
- 75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
- Median price target $99, i.e. +11% from the current price ($90).
- The most reliable firm on MMSI, Canaccord Genuity (63% hit rate, 19 scored calls), targets $94 (call made on August 3, 2026, maturing on August 3, 2027) (+5%) in its most recent call, and $104 (call made on October 16, 2025, maturing on October 16, 2026) (+16%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 8 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on MMSI
Median target $99 (+11%) · 8 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Merit Medical Systems, Inc. now?
We won't decide for you. The facts: 75% of analysts rate it a buy, median target $99 (+11%), and Canaccord Genuity (most reliable on MMSI, 63%) targets $94. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Merit Medical Systems, Inc.?
Not according to analysts: the median target ($99) is still +11% above the current price ($90) (most reliable on MMSI: Canaccord Genuity, 63%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Merit Medical Systems, Inc. still worth investing in?
It depends on the gap between the price ($90) and its estimated value: analysts target $99 on median (+11%), with 75% buys (most reliable on MMSI: Canaccord Genuity, 63%). Cross-check with their real reliability on MMSI and the cautions above. Information, not advice.
What's the main risk in buying MMSI?
The consensus is not unanimous: of 8 ratings, 2 are neutral.
→ Go deeper: the full Merit Medical Systems, Inc. profile (consensus, analyst reliability, price target, performance).